Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Merck
UBS
Moodys
Farmers Insurance
McKinsey
Express Scripts
Healthtrust

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JANUVIA

« Back to Dashboard

Clinical Trials for Januvia

Trial ID Title Status Sponsor Phase Summary
NCT00086502 Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00086515 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00087516 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00337610 Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus Completed Merck Sharp & Dohme Corp. Phase 3 A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
NCT00350779 Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) Completed Merck Sharp & Dohme Corp. Phase 3 A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.
NCT00364377 Incretins in Impaired Fasting Glucose Completed Mayo Clinic Phase 4 People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hormone, called glucagon-like peptide-1 (GLP-1), is normally released by the intestine in response to the presence of food. This hormone acts like a messenger between the intestine and the pancreas to raise insulin levels, and therefore, lower blood sugars. Sitagliptin is effective in people with diabetes, however, this study is being done to determine if Sitagliptin is effective in people with high fasting glucose who do not yet have diabetes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Januvia

Condition Name

Condition Name for Januvia
Intervention Trials
Type 2 Diabetes Mellitus 34
Type 2 Diabetes 26
Diabetes Mellitus, Type 2 13
Diabetes 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Januvia
Intervention Trials
Diabetes Mellitus 86
Diabetes Mellitus, Type 2 80
Diabetes Mellitus, Type 1 11
Hyperglycemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Januvia

Trials by Country

Trials by Country for Januvia
Location Trials
United States 234
Canada 13
Korea, Republic of 12
Italy 12
Mexico 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Januvia
Location Trials
Texas 16
California 13
Georgia 13
Ohio 13
Florida 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Januvia

Clinical Trial Phase

Clinical Trial Phase for Januvia
Clinical Trial Phase Trials
Phase 4 56
Phase 3 30
Phase 2/Phase 3 1
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Januvia
Clinical Trial Phase Trials
Completed 75
Recruiting 28
Unknown status 11
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Januvia

Sponsor Name

Sponsor Name for Januvia
Sponsor Trials
Merck Sharp & Dohme Corp. 41
Emory University 7
AstraZeneca 6
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Januvia
Sponsor Trials
Other 118
Industry 85
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKinsey
Harvard Business School
UBS
Baxter
Colorcon
Argus Health
Julphar
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.